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Abstract
Purpose Screening of Gardner syndrome (GS) patients is
tailored towards prevention of colorectal cancer (CRC).
However, many patients suffer from desmoid tumors, which
are challenging to treat due to invasive growth and local
recurrence. The aims of our study were to determine the
effectiveness of screening in GS and analyze outcome of
desmoid tumors by treatment modality.
Methods This was a cohort study of a family of 105 descend-
ants with GS. All family members who agreed were screened
by endoscopy, and colorectal resection was performed upon
pending malignancy. Resectable desmoids were excised,
whereas large tumors were treated by a combination of bra-
chytherapy (BT) and radiotherapy (RT). Main outcome meas-
ures were the incidence of CRC and overall and disease-
specific mortality (ClinicalTrial.gov ID NCT01286662).
Results Thirty-seven of 105 family members have GS. Pre-
ventive colorectal resections were performed in 16 patients
(15 %), with one death due to gastric cancer. In four patients
who denied screening endoscopy, invasive tumors of the
colon (three patients) and stomach developed. Of 33 des-
moid tumors, 10 (30 %) were located in the mesentery, 17
(52 %) in the abdominal wall, and 6 (18 %) in extra-
abdominal sites. Excision of 12 desmoids was performed
in eight patients. Four desmoids were treated by BT and RT
and showed full or partial remission.
Conclusions Provided adequate screening, good long-term
control of colorectal tumors is achievable. However, des-
moid tumors determine survival and quality of life in many
patients. Our data suggest good local control using a com-
bination of brachytherapy/radiotherapy in large desmoids
unsuitable for surgical resection.
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Introduction
In 1950, Eldon J. Gardner first described a kindred of
patients presenting with familial adenomatous polyposis
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(FAP) in combination with various skin and soft tissue
tumors [1]. Although the term “Gardner syndrome” (GS)
describes more of a historically coined variant of FAP rather
than a distinct subtype of the disease [2–4], the term is
usually reserved for patients in whom extraintestinal mani-
festations are especially prominent and relevant during the
course of their disease [5–7].
Since 1978, our group of physicians has been treating a
family of GS patients in the remote southeastern part of
Switzerland. Similar to ethnic subgroups with little genetic
admixture such as the Amish community in Northern Amer-
ica, this kindred has been living in an area of alpine Switzer-
land with minimal migration of residents, thereby passing
on the distinct genetic Gardner subtype in a manner allow-
ing population-based genetic analysis. Affected family
members present with the phenotype of an attenuated form
of FAP (AFAP), distinguished from classic FAP by the
presence of fewer colonic adenomas, a lower cancer pene-
trance, and an older age distribution of adenomas as well as
carcinomas. In most cases, the syndrome is caused by auto-
somal mutations in the APC gene. These mutations have
been verified since the early 1990s. In this kindred, the APC
germ line mutation c.5942delAwas identified; this mutation
leads to a frameshift at codon 1981 and results in a prema-
ture stop codon (p.Asn1981IlefsX62) [8].
As in most FAP patients, the mainstay in the management
is repeat clinical and endoscopic screening to ensure timely
colonic resection (usually in the form of subtotal colectomy
or proctocolectomy with ileal pouch-anal anastomosis—
IPAA) in patients developing malignancy. Experts on hered-
itary gastrointestinal cancer recommend initial sigmoidos-
copy in individuals with positive genetic testing and a
classical FAP variant at the age of 10–12 years [9]. The
same is recommended in patients with a positive family
history and negative genetic testing, whereas in AFAP mem-
bers with an identified mutation, initial colonoscopy is in-
dicated at the age of 18–20. Thereafter, repeat endoscopy
should be performed every 2 years; once adenomas are
detected, annual colonoscopy should be performed until
colectomy [9]. In addition, 10–15 % of GS patients develop
desmoid tumors which frequently develop following surgi-
cal resection in accessible areas such as the abdominal wall,
or in sites unsuitable for resection like the intestinal mesen-
tery. Despite their lack of metastatic potential, desmoids
cause significant morbidity and mortality due to their ability
to surround, compress, and erode adjacent tissues, providing
a challenge to surgeons and oncologists alike. Affected
patients suffer from prolonged and often lethal courses.
The aim of our present study was twofold. First, we wished
to investigate whether early genetic testing, repeat clinical and
endoscopic testing, and prophylactic colectomy were associ-
ated with acceptable morbidity and mortality in GS. Secondly,
we wished to better characterize extraintestinal manifestations
with an emphasis on treatment and outcome of desmoid
tumors in our GS population.
Methods
Study design, eligibility criteria, and outcome variables
Prognostic cohort study: Since 1978, our group of physicians
has been following a family of 105 members (43 women)
from three generations of Gardner syndrome patients living in
southeastern Switzerland. They are all direct descendants of a
couple who lived at the end of the nineteenth century, and of
which we know that five of their eight children died from
gastrointestinal cancer [10]. They all suffer from an identical
mutation of the APC gene that is being passed from one
generation to the next. Both family members with confirmed
APCmutations and those unwilling to undergo genetic testing
but showing typical phenotype (endoscopic presence of mul-
tiple adenomas) were eligible for this study and defined our
sample size. Operations were performed at the local hospital
in cooperation with pathology services from a regional referral
center and (radio-) oncology and genetic counseling services
from two national university hospitals. Outcome variables
included overall survival, incidence of intestinal and extrain-
testinal neoplasms, and treatment-specific recurrence rates and
survival.
Diagnostic criteria: molecular and genetic testing
All family members at risk for the previously identified
APC germ line mutation (c.5942delA) were counseled and
offered genetic testing by direct DNA sequencing [3, 4].
Genetic testing of our patient cohort was started in 1995
[11]. Routine testing was recommended in adolescents by
the age of 16 in order to timely identify patients in need of
endoscopic screening and to reassure individuals not carry-
ing the mutation. All tests were performed twice from two
different samples of whole blood drawn on different days to
minimize false-positive testing.
Clinical and endoscopic screening program
In patients with positive APC gene mutations, endoscopic
screening was recommended to begin at the age of 16 years.
Colonoscopy was indicated in patients with confirmed APC
mutation and those who did or could not undergo genetic
testing but who were related to known carriers of the muta-
tion. Colonoscopy was recommended every 2 years in
patients without adenomas; once adenomas were detected,
annual colonoscopy was recommended.
Gastroscopy was performed upon detection of colorectal
adenomas, or earlier upon onset of any upper gastrointestinal
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symptoms. The extent of duodenal polyposis was assessed
using the Spigelman classification and patients were moni-
tored accordingly [12]. In case of few, small duodenal adeno-
mas, screening and endoscopic removal was continued,
whereas resection was encouraged in multiple or dysplastic
adenomas (Spigelman IV).
Treatment of colonic adenoma, carcinoma, and soft tissue
tumors
Preventive resections were recommended to patients with
confirmed dysplasia and/or endoscopically uncontrollable
numbers of adenomas. Subtotal colectomy with ileorectal
anastomosis (IRA) was the procedure of choice in our
patients due to the clinical phenotype of GS with predomi-
nantly right-sided polyposis and no or only moderate in-
volvement of the rectum. Despite the risk of late rectal
cancer and the need for lifetime follow-up in patients with
IRA, we and others believe that this procedure is justified in
GS due to its technical simplicity, good functional results,
and lower perioperative morbidity compared to IPAA [13].
Desmoids and other soft tissue tumors
Desmoids of the abdominal wall were treated by wide
excision in symptomatic patients or those exhibiting rapid
growth and were routinely followed by CT. Recurrent des-
moids were treated by radical resection or a combination of
percutaneous radiotherapy (RT) and brachytherapy (BT) if
unsuitable for resection. Intra-abdominal desmoids were
usually considered nonresectable due to invasive growth in
the intestinal mesentery and their often multifocal and late
clinical appearance.
Statistical analysis
The study is registered at the National Institute of Health’s
registry (ClinicalTrial.gov ID NCT01286662). Descriptive
analyses and univariate statistical comparisons were per-
formed using Sigma Stat 3.11.0, Systat Software, Inc.
Results
Thirty-seven of the 105 members of this family were diag-
nosed with Gardner syndrome, either by positive genetic test-
ing (27 patients) or by their phenotype (10 patients). The mean
age at time of testing was 30 years (range 5–73). Genetic
testing was done in 52 family members (27 positive, 25 neg-
ative). The APCmutation status of the remaining 43 patients is
unknown, either because they declined genetic testing, have
not undergone colonoscopy for age reasons, or were lost to
follow-up during the course of their lives (Table 1).
Thirty-two of the 37 GS patients were screened using
colonoscopy. The five remaining patients denied screening
endoscopy. The youngest patient undergoing endoscopy was
12 years, and the youngest patient showing colonic polyposis
was 14 years old. The most prevalent endoscopic findings of
the gastrointestinal tract are listed in Table 2. In our series,
patients most frequently presented with attenuated polyposis
with a predominantly right-sided affection of the colon, main-
ly the cecum and the ascending colon. In 18 patients, few
polyps (100 or less) were observed, whereas five patients
showed up to 1,000 polyps. The rectum was mildly affected
in 14 cases. Altogether, 18 patients (17 % of the entire kindred
and 49 % of patients genotypically and/or phenotypically
positive for GS) had to undergo colonic resections, and 7
patients had to undergo a total of 10 resections for extraco-
lonic tumors. Overall mortality throughout the entire time
period was six patients (16 % of all patients with Gardner
syndrome), three of whom died from colorectal carcinoma,
one from gastric carcinoma, and two from mesenteric des-
moids tumors.
A total of 34 adult family members (32 %) either de-
clined to undergo genetic testing or screening endoscopies
Table 1 Prevalence of Gardner syndrome in the study cohort
Established diagnosis of GS Genotype positive—27 (26 %)
Phenotype positive—10 (10 %)
Diagnosis of GS ruled out Genotype negative—25 (24 %)
Juvenile family members at
risk w/o genetic testing
or colonoscopya
9 (8 %)
Adult family members at risk
who decline genetic testing
and colonoscopy
10 (10 %)
Lost to follow-up 24 (22 %)
Entire cohort 105 family members (100 %)
GS Gardner syndrome, w/o without
a Endoscopy planned at age 16
Table 2 Gastrointestinal tumors and polyps (36 patients, 93 tumors)
Site Tumor No. of patients
Stomach Fundic gland polyposis 9
Adenoma 15
Ulceration/gastritis 9
Dysplasia/adenocarcinoma 3
Duodenum Adenomas 13
Jejunum Adenocarcinoma 1
Ileum Polyps 3
Colon Adenomas/polyps 23
Adenocarcinoma 2
Rectum Adenomas/polyps 14
Adenocarcinoma 1
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or were lost to follow-up in the course of the entire obser-
vation period (Table 1). In addition, two patients with his-
tologically confirmed colorectal carcinoma refused surgical
treatment.
Outcome related to colorectal adenoma and carcinoma
Of the entire cohort, 18 patients underwent colorectal resec-
tions. Sixteen underwent preventive resections (15 colecto-
mies with ileorectal anastomosis and one left colectomy)
due to endoscopic findings of either too numerous or dys-
plastic adenoma and two patients because of colorectal
cancer (CRC) without previous suspicion of dysplastic ad-
enoma (one proctocolectomy and one resection of the trans-
verse colon). Of all patients with colorectal resections, 16
remained free of recurrence for a mean 93 months (range
14–387), whereas two patients died from recurrent CRC.
Both patients either refused screening endoscopy or surgical
resection at a premalignant state. One patient died from
gastric cancer and two from mesenteric desmoids after
48 months (range 24–103). Most importantly, however,
none of the patients who underwent screening endoscopy
followed by preventive colectomy for suspicious endoscop-
ic findings died from intestinal neoplasms.
Treatment and outcome of desmoid tumors
Fifteen patients (5 women, 10 men) developed a total of 33
desmoids tumors (14 % of the entire family, 41 % of Gardner
patients at a mean age of 43 years [31–77 years], Table 3).
Most desmoids (17 tumors, 52 %) were found in the abdom-
inal wall (Fig. 1a). Ten patients suffered from solitary mesen-
teric desmoids (30 %, Fig. 1b). Six desmoids (18 %) were
located in extra-abdominal locations (back, groin, thigh, but-
tocks). Sixty-one percent occurred in context with pervious
surgery (mainly laparotomy) after a median interval of
39 months after surgery (range 6–94 months). Thirteen des-
moids developed in patients without prior surgery (one mes-
enteric desmoid, six abdominal wall desmoids, six others).
Ten abdominal wall desmoids could be treated by wide exci-
sion alone (Fig. 2), with three recurrences in one single patient
within 28 months. Complications in patients with progressive
mesenteric desmoids were ureteric obstruction in two patients
and bowel obstruction in two patients with stage III mesen-
teric desmoids, one of whom was treated by small bowel
resection and intestinal transplantation.
Recurrences of abdominal wall desmoids were treated by
repeat local excision. Six patients stayed recurrence-free for
a mean follow-up of 70 months (range 6–120 months). The
remaining one patient decided to discontinue follow-up, and
his status is unknown. From 2006 onwards, two desmoids
were treated by high-dose radiation (HDR) brachytherapy
and two others by a combination of HDR brachytherapy and
percutaneous radiotherapy. All were recurrent desmoids
which were unsuitable for resection due to their large size
at presentation. Desmoid tumors treated in this manner
showed complete and partial remission in two cases each,
with an average length of follow-up of 19 months (range
13–25 months, Fig. 3). Indications for BTwere large tumors
requiring plastic coverage if resected and patients denying
surgery. In addition, desmoids had to be of adequate size to
be properly exposed to the applicators (Fig. 4). Clinoril and
tamoxifen was used in five patients with mesenterial des-
moids that were unsuitable for resection, or in patients
reluctant to undergo surgical therapy.
Osteoma and other extracolonic manifestations
A disproportionate number of GS patients developed a
variety of both benign and malignant extracolonic tumors,
including a renal cell carcinoma, pancreatic insular carcino-
ma, Hodgkin and non-Hodgkin lymphoma, uterus myoma,
adrenal incidentaloma, cervical carcinoma, and one endo-
metrioma. Eight patients developed a total of 12 osteoma
which were located in the skull (seven), spine (two), and
pelvic bone (three). Two such tumors were located in the
mandibula of separate patients and required surgical exci-
sion due to progressive growth. No case of thyroid carcino-
ma occurred in our patient cohort.
Discussion
Since Elrond J. Gardner’s original description in the 1950s,
a number of case reports and small series have been pub-
lished which describe this unique variant of FAP. Most
authors agree on the need for early screening endoscopy
followed by colectomy upon detection of dysplasia or en-
doscopically uncontrollable adenomatosis [9, 14, 15]. Less
consent, however, exists on the management of associated
desmoid tumors. In our present study, we have been
privileged to follow on a large number of patients in a
socially and geographically “contained” environment, pro-
viding us the unique opportunity to study not only problems
related to colonic adenomatosis and its consequences, but
also the occurrence and management of extracolonic mani-
festations in a large number of patients. In summary, we
believe to contribute to the following issues related to Gard-
ner syndrome patients:
Screening Our data show that early screening endoscopy in
patients with identified APC gene mutation, and subsequent
prophylactic colectomy in patients with dysplasia or sub-
stantial adenomatosis reliably prevents the occurrence of
CRC in Gardner patients. In fact, none of the members of
this family willing to participate in our surveillance program
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with genetic testing, screening endoscopy, and prophylactic
colectomy developed CRC. These encouraging results sup-
port the findings of Heiskanen et al., who found a mortality
rate in FAP patients with family screening approaching that
of the normal population up to 18 years after colectomy
[16].
With respect to the surgical management of colorectal
polyposis, two main options exist: colectomy with IRA and
proctocolectomy with IPAA. Given the phenotypic presen-
tation of our cohort, we have consistently utilized IRA in
these patients, most of whom have experienced excellent
functional outcome and quality of life. Due to this pheno-
type’s distinct affection of the right-sided colon, we and
others see no need for IPAA due to its higher morbidity
and lower postoperative quality of life [17]. There was also
no need for a secondary conversion to IPAA as none of our
patients developed significant rectal polyposis, adenoma, or
cancer. In fact, it is our observation that the numbers of
rectal polyps appeared to decrease after colectomy even
though we are lacking data to confirm this assumption. In
addition, life-long repeat endoscopic surveillance and abla-
tion of polyps is mandatory following both IRA and IPAA,
since carcinoma may also develop in the pouch [18, 19]. In
patients who had undergone colectomy, mortality mainly
arose from desmoid tumors and extracolonic gastrointestinal
malignancies, which supports previous studies on the causes
of mortality in FAP [16, 20, 21].
A
B
Fig. 1 Desmoids of the abdominal wall (a) and the intestinal mesen-
tery (b). CT scanning; note the epifascial location in (a) and the
proximity to the mesenteric root in (b)
Fig. 2 Surgical treatment of desmoid tumors. En bloc resection of
skin, subcutaneous fat, desmoid tumor, and adjacent abdominal wall
musculature and fascia due to locally invasive growth and frequent
recurrence
Fig. 3 Brachytherapy of desmoid tumors before (left) and 2 years after
brachytherapy (right). Good remission with only residual thickening of
rectus sheath after brachytherapy
Fig. 4 HDR brachytherapy applicators. Seven applicators in situ dur-
ing treatment of a desmoid of the lower abdominal wall considered
unsuitable for resection and direct closure
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We found that desmoids develop in a significant percent-
age of patients. The greatest challenge posed by these
tumors is their locally invasive growth in sites precluding
radical resection. Several potential risk factors for the de-
velopment of desmoids are being discussed in the literature,
and previous surgery is believed to promote growth of
desmoids [22]. Two thirds of the desmoids in our patients
occurred after a mean interval of 34 months after colectomy.
Partly, these results may be influenced by the fact that the
mean age at diagnosis of desmoid tumors is 48 years (range
31–73 years), whereas colectomy is usually performed at a
younger age of 44 years (range 30–61 years), thereby maybe
implicating a false causative relationship. In addition, no
desmoids at all were detected in seven colectomy patients
during a mean follow-up of 104 months.
The location of the genetic mutation also seems to influ-
ence the development of desmoids (higher risk in mutations
beyond codon 1444, or in mutations at the 3′-end of the
codon) [23]. Our results, however, show pronounced intra-
familial variations of the phenotype with a seemingly un-
predictable clinical course, indicating the influence of
genetic factors other than the APC mutation itself [11].
Best results were obtained in patients with abdominal wall
desmoids at an early stage appropriate for radical resection
and direct closure. Resection of desmoids was generally rec-
ommended in symptomatic patients and those exhibiting rapid
growth, whereas observation with frequent follow-up was
done in patients with small, asymptomatic desmoids and those
unwilling to undergo resection. Alternatively, we used HDR
brachytherapy with good success in four patients with large
recurrent tumors unfit for resection. No recurrence was ob-
served throughout their follow-up. Despite our limited expe-
rience, we believe that HDR brachytherapy may provide an
alternative to resection in patients that are unfit for surgery or
in whom the size or location of the desmoids precludes radical
resection, since HDR brachytherapy is known to improve
local control of desmoid tumors [24].
The greatest therapeutic challenge was desmoids arising
within the intestinal mesentery. In these patients, operative
treatment is associated with serious morbidity and mortality
arising from intestinal ischemia following radical resection,
anastomotic failure, or late small bowel obstruction. Fur-
thermore, evidence exists that resection of mesenteric des-
moids may in fact stimulate tumor growth, which is why
treatment is often directed only at relieving specific local
consequences such as small bowel obstruction or ischemia
[25, 26]. Chemotherapy has so far not been part of our
treatment rationale in desmoid patients due to its controver-
sial benefits; however, two recent trials have shown im-
proved progression-free survival rates in patients with
nonresectable desmoids treated with doxorubicin or imati-
nib, thereby potentially offering a true benefit in this diffi-
cult to treat subgroup of patients [27, 28].
A point of interest is the phenotype–genotype correlation
in GS: Since 1992 several attempts have been made to
correlate specific APC mutations with clinical phenotypes
and explain clinical variability on the basis of different
mutations. However, there is considerable variability in the
expression of specific phenotypes within families and even
among individuals with identical mutations [29, 30]. In our
family, the mutation is located on exon 15, codon 1981
which causes an attenuated form of polyposis with fewer
adenomas (100 or fewer).
Finally, although sophisticated screening and surveil-
lance programs are available, a considerable number of
individuals refuse participation or are reluctant to act once
their disease has been diagnosed. We have encountered this
denial frequently and have sadly had to observe progression
into fatal cancer in three patients. While the problem of
noncompliance pertains to many problems in medicine, the
high percentage of individuals that remain reluctant to un-
dergo preventive testing remains of great concern. In our
opinion, this phenomenon emphasizes the need for a con-
tinuous follow-up of all individuals at risk through the same
credible group of physicians and emphasizes the need for a
sustainable physician–patient relationship throughout the
life of any Gardner patient.
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